Sprycel

(dasatinib (anhydrous))

Uses, side effects, dosage information & price range

Bristol-Myers Squibb Pharma EEIG

About this medicine

Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. Sprycel is indicated for the treatment of adult patients with: newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate; Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

Dasatinib AccordComposition: dasatinib (anhydrous)Accord Healthcare S.L.U.

Price on RequestView Details →

Dasatinib AccordpharmaComposition: dasatinib (anhydrous)Accord Healthcare S.L.U.

Price on RequestView Details →

Key Information

Salt / Composition

dasatinib (anhydrous)